Potential mechanisms of resistance to cytarabine in AML patients. - Wikidata - awgldk - TriplyDB

Potential mechanisms of resistance to cytarabine in AML patients.

Potential mechanisms of resistance to cytarabine in AML patients.

http://www.wikidata.org/entity/Q34128239

about

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.Physiological and pharmacological roles of nucleoside transporter proteins.Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies.Assessment of drug resistance in acute myeloid leukemia.Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.Nucleoside analogue delivery systems in cancer therapy.Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1 Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.Mouse models of human AML accurately predict chemotherapy response Genetic factors influencing cytarabine therapy.Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.Clinical potential of elacytarabine in patients with acute myeloid leukemia.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.Nucleoside analogs: ready to enter the era of precision medicine?Pharmacogenomics and the treatment of acute myeloid leukemia.Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases.Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.Determination of optimal replicate number for validation of imprecision using fluorescence cell-based assays: proposed practical method.Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.

P2860

Q27014790-D7AC2D1D-07EC-490C-A9FA-8900A8844E77 Q27488307-CD8FFB7F-40BA-4810-BF51-48F61D8B07A8 Q28483881-02007E45-027C-4966-9FA7-4D2A496D8941 Q30490446-CF13845C-C590-4F20-B765-7509A560B5AE Q33442358-96DCA9C0-C75D-4D0F-9E87-6C0FF2ED962A Q33922485-74C53DBF-5C23-4713-99E8-13C6B4D1EFD0 Q34314177-BB1C7873-0883-42ED-925E-990FBE6E3450 Q34548815-2DF5CAA3-9F4B-41D8-960D-19EB176FC2D1 Q34792283-DA803DA2-065C-40CA-A19F-E7A7E5323E85 Q35077712-AABB8EBB-1A34-463E-99EE-267F13405D58 Q35114704-82FF4437-7E4E-4812-856A-B786D90E97DB Q35198909-F205A5EB-42E2-41F3-8DD2-C2748A2D7604 Q35878296-729D5B62-B725-42A4-9CF8-ACF4F5269ECB Q35994964-1BE62523-7975-4D14-8C83-CAA0A2F623E6 Q36289307-DB31D74E-E8D1-4071-8E4A-4CBA6E1A297D Q36873301-5654139B-9C27-4D12-B035-8A8B8C2B4FF0 Q36924856-18674F03-B7DA-4268-A4BA-7E8F35ED0AB3 Q36945847-ACD3BED4-E726-45A1-9B2C-CFBA55A69EE4 Q36962978-12A0061E-9B46-4B2E-A0EA-790C044F8933 Q36966019-5157ED30-15FA-4831-8FBE-E0DAA58BEFB5 Q36981855-850C1621-105B-45DE-B1E2-49B0D2A27833 Q37119899-969A4B53-0525-415A-AA08-BCA8AEA498DB Q37152257-0E0A91D9-5E94-452E-AC2F-E186621D651D Q37618228-8965422C-6688-4A42-BAA6-AC653843387A Q38078423-2D7B9BE3-6E90-4754-BCBA-1FFA8A6C7AB6 Q38282095-C90D00D0-C237-4A2E-B7F0-BF8D2A938B80 Q38285621-F9C9E0AF-4AA0-4966-ABC8-B8D1C28B3E4F Q38757910-7276AB1C-8B33-4FD4-8BCA-E8E802D9342B Q38842938-872C0CA8-71CE-4C9D-919C-D369ABEF7FA3 Q38887034-2FFE13D2-C87D-4454-BA6A-5ED365298DBC Q39334849-8577C9A6-E9B1-4CD9-A820-F4C67E558E58 Q39374988-E4C6C386-C2A4-4991-92FE-A3169EF2D0EE Q39965228-1254E8F7-9030-4989-B6C8-F14D42D30D5B Q40506711-4C7F41F0-28D3-43B3-B4DB-B4D3C1D2A6F0 Q41816813-41AA4063-B6A0-4187-9DDA-A9F6156630B8 Q42287089-A3FDFEE1-4107-420D-836F-B3D4F240AAA9 Q42725619-806B2A8F-4550-40BC-B994-636D5763E125 Q46986983-F6B7CE92-35F1-4140-8801-067B089D4C3C Q47137275-6AC88F65-ABDE-4E70-A01B-C5904E73E31F Q47375547-03FC530E-A162-468D-957C-6E0781F58468

P2860

Potential mechanisms of resistance to cytarabine in AML patients.

http://www.wikidata.org/entity/Q34128239

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Potential mechanisms of resistance to cytarabine in AML patients.

@ast

Potential mechanisms of resistance to cytarabine in AML patients.

@en

Potential mechanisms of resistance to cytarabine in AML patients.

@nl

type

label

Potential mechanisms of resistance to cytarabine in AML patients.

@ast

Potential mechanisms of resistance to cytarabine in AML patients.

@en

Potential mechanisms of resistance to cytarabine in AML patients.

@nl

prefLabel

Potential mechanisms of resistance to cytarabine in AML patients.

@ast

Potential mechanisms of resistance to cytarabine in AML patients.

@en

Potential mechanisms of resistance to cytarabine in AML patients.

@nl

P1433

Q34128239-5885AACC-CD48-4ED4-8234-95CC1ED05583

P1476

Q34128239-9F5A6F0F-1EE8-48BF-B6D3-EF99D45954ED

P2093

Q34128239-06291CB9-FC5B-4AA4-9631-F9668CFC157E

Q34128239-11217C9E-44AB-494D-B054-246ECA7B0E0F

Q34128239-218F0FBB-907B-49F4-B439-8B0588842F9E

Q34128239-277F7BFF-23EF-4B1E-B2D2-40AB608A16D0

Q34128239-3CF31B01-B039-46A8-A468-A1B8489F75A7

Q34128239-E59D0AF7-9BDA-477A-878F-4864D3652FE5

Q34128239-FEC9F5B7-00BB-4927-BAB7-5D3915F4E072

P304

Q34128239-B44B2550-4507-404A-A449-055D42C80DCA

P31

Q34128239-D2F1FEDE-63CB-4B6C-A085-C3F59820CF6B

P356

Q34128239-43068A6F-2FEA-4ED2-A45F-41201D969E6B

P433

Q34128239-8881ABEE-1B32-4D28-A3E5-6705387B0AEF

P478

Q34128239-24C55349-DA12-47D1-AE04-80A2DE3E77F4

P577

Q34128239-F3918935-56B4-4271-9C0E-E2F528FFC6C3

P698

Q34128239-A5B7ED8F-A2BB-42B2-8CDF-E69763FB421C

P921

Q34128239-9B57F36F-D72E-4011-BB0F-C33AED60A5BD

P356

S0145-2126(01)00184-9

P1433

Leukemia Research

P1476

Potential mechanisms of resistance to cytarabine in AML patients.

@en

P2093

Assia El Jafaari

http://www.w3.org/2001/XMLSchema#string

Carlos M Galmarini

http://www.w3.org/2001/XMLSchema#string

Charles Dumontet

http://www.w3.org/2001/XMLSchema#string

Emeline Cros

http://www.w3.org/2001/XMLSchema#string

Fabien Calvo

http://www.w3.org/2001/XMLSchema#string

Philippe Rousselot

http://www.w3.org/2001/XMLSchema#string

Xavier Thomas

http://www.w3.org/2001/XMLSchema#string

P304

621-629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0145-2126(01)00184-9

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12008078

http://www.w3.org/2001/XMLSchema#string

P921